Celyad Oncology S.A.
Celyad Oncology S.A. (CYAD) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CYAD · as of Sep 30, 2023
Ownership Breakdown
1
Institutional Holders
▼ 1 vs Q2
$5,904
Total Inst. Value
▼ $3,370 vs Q2
30.29M
Shares Outstanding
freeFloat 44.82%
9,000
13F Shares Held
▼ 18,277 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CYAD largest shareholders · institutional ownership
Q3 2023 · SEC 13F
Showing top 2 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
RHUMBLINE ADVISERS pharmaceutical preparations | 9.0K | 3.98% | 3.98% | $5.90M | Nov 9, 2023 | — held |
BAADER BANK AKTIENGESELLSCHAFT pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Nov 14, 2023 | EXIT |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2023 vs prior quarter
Q3 2023
0
Increased
+0 shares0
New Positions
first time holders0
Decreased
−0 shares1
Sold Out
fully exitedNet shares change (top 50)
+0
+0 / −0
Net new holders
-1
0 new / 1 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CYAD insider trading · insider activity
Source: SEC Form 4
Recent Insider Transactions
Showing 10 most recent · Common Stock only
No recent insider transactions reported.
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Celyad Oncology S.A. (CYAD) is primarily owned by institutional investors, who hold approximately 0.0% of total shares outstanding. Company insiders own approximately 55.18%, while retail and public investors account for the remaining 44.79%.
The largest institutional shareholder of Celyad Oncology S.A. is RHUMBLINE ADVISERS, holding approximately 9,000 shares — equal to 3.98% of outstanding shares — as of September 30, 2023.
A total of 1 institutional investors currently hold CYAD stock, with a combined institutional value of approximately $5,904 as of the most recent 13F filing period.
Frequently asked questions
CYAD ownershipCelyad Oncology S.A. (CYAD) is primarily owned by institutional investors, who hold approximately 0.0% of shares. The largest shareholder is RHUMBLINE ADVISERS with a 3.98% stake. Company insiders hold 55.18%. Data sourced from SEC Form 13F as of September 30, 2023.